Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CDTX

CDTX - Cidara Therapeutics Inc Stock Price, Fair Value and News

$221.38 
Market Closed

9/100

CDTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

CDTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$176.82

Target 3M

$198.93

Target 6M

$187.88

CDTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDTX Price Action

Last 7 days

0.1%

Last 30 days

0.0%

Last 90 days

116.7%

Trailing 12 Months

709.6%

CDTX RSI Chart

CDTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CDTX Valuation

Market Cap

7.0B

Price/Earnings (Trailing)

-37.68

Price/Sales (Trailing)

5.4K

EV/EBITDA

-39.04

Price/Free Cashflow

-52.35

CDTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$176.82

Target 3M

$198.93

Target 6M

$187.88

CDTX Fundamentals

CDTX Revenue

Revenue (TTM)

1.3M

CDTX Earnings

Earnings (TTM)

-184.7M

Earnings Growth (Yr)

-420.69%

Earnings Growth (Qtr)

-223.64%

CDTX Profitability

EBT Margin

-13355.92%

Return on Equity

-43.74%

Return on Assets

-35.62%

Free Cashflow Yield

-1.91%

CDTX Investor Care

Shares Dilution (1Y)

346.16%

Diluted EPS (TTM)

-9.53

CDTX Alerts

  • 1 major insider buys and 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202418.0M13.2M4.0M1.3M
202325.0M25.8M28.5M23.3M
202251.9M23.3M22.8M23.5M
202111.9M41.4M46.1M49.6M
202023.9M26.8M10.2M12.1M
201900020.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cidara Therapeutics Inc

CDTX
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
 CEO
 WEBSITEcidara.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES73

Cidara Therapeutics Inc Frequently Asked Questions

CDTX is the stock ticker symbol of Cidara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Jan 08 2026, market cap of Cidara Therapeutics Inc is 6.96 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CDTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether CDTX is over valued or under valued. Whether Cidara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cidara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDTX.

As of Thu Jan 08 2026, CDTX's PE ratio (Price to Earnings) is -37.68 and Price to Sales (PS) ratio is 5.44 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDTX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Cidara Therapeutics Inc has provided -0.042 (multiply by 100 for percentage) rate of return.